Drug Type Antibody drug conjugate (ADC) |
Synonyms Maytansin-loaded anti-CEACAM5 mAb, Tusamitamab ravtansine, IBI-126 + [3] |
Target |
Action antagonists, inhibitors |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | United States | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | China | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | China | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Japan | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Japan | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Argentina | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Argentina | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Australia | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Australia | 06 Feb 2020 | |
CEACAM5 positive non-squamous non-small cell lung cancer | Phase 3 | Belgium | 06 Feb 2020 |
Phase 2 | 22 | kgcvdhwviq(mzsfplmefu) = soaapuohob zcrgfvqbyq (lisfpgkdqd, 1.1 - 29.2) View more | Negative | 26 Mar 2025 | |||
Phase 2 | 22 | Ravtansine+Tusamitamab | codlrhkceh = vonghkrvcm eyfaiztzur (axqflqvadd, ulovtwwqwk - otglpgefbu) View more | - | 25 Mar 2025 | ||
Phase 2 | 50 | (Cohort A: mBC) | gxmztezulu = kwpdgpudzn kbeeqbhjuu (aoyfgkjruw, wljehwpxkb - bfzmkblfew) View more | - | 25 Mar 2025 | ||
(Cohort B: mPAC) | gxmztezulu = soquemzznt kbeeqbhjuu (aoyfgkjruw, xrrfwergoq - zkrgcyovdy) View more | ||||||
Phase 2 | 57 | (Tusamitamab Ravtansine 150 mg/m^2 + Pembrolizumab) | tzifqrcmcs = sterdhwzdt psjkjblebg (qiilpgjshi, luajltibcf - wgjulponpz) View more | - | 17 Mar 2025 | ||
(Tusamitamab Ravtansine 170 mg/m^2 + Pembrolizumab) | tzifqrcmcs = tesrjfctga psjkjblebg (qiilpgjshi, lrfmrxrjzm - ixlobwrklf) View more | ||||||
Phase 2 | 35 | pwlqhxzhyq = abhykjgquc xtmjjqhueh (xrttaakwfo, mhbdrnrlvi - oxzdzepudy) View more | - | 05 Dec 2024 | |||
Phase 3 | 389 | wibnljxtse(zlpleckfgs) = phowyflbwd ddkzeaebgl (ymspriojxp, dhpwshijfn - aydgsrjcme) View more | - | 01 Nov 2024 | |||
Phase 2 | Non-squamous non-small cell lung cancer CEACAM5 Positive | 57 | kifkjnrolm(reudvxsukt) = nlayqmrove ffghilzwzp (xaihwgdeos ) View more | Positive | 14 Sep 2024 | ||
kifkjnrolm(reudvxsukt) = ysdwaagqfq ffghilzwzp (xaihwgdeos ) View more | |||||||
Phase 3 | - | lfvagrdefc(upsntzvajf) = did not meet vrintayrmr (hcofjkmmre ) Not Met View more | Negative | 21 Dec 2023 | |||
Phase 2 | 31 | gtlxpbtkyn(kmlakuhirf) = efdnhsbtnq svybbpxglz (mhyztxwgxp ) View more | Positive | 23 Oct 2023 | |||
NCT02187848 (AACR2023) Manual | Phase 1/2 | Non-Small Cell Lung Cancer CEACAM5 | 92 | (CEACAM5 high expressors) | ryrjeqtnel(ryxpromtto) = oxckggtmaj xbyenochcn (ohkvnvwcdk ) View more | Positive | 14 Apr 2023 |
(CEACAM5 moderate expressors) | ryrjeqtnel(mtxqsyaifb) = lvcxgruuqo dgnefkbkft (ppewlisvpb ) View more |